Squarepoint
SGMT icon

Squarepoint’s Sagimet Biosciences SGMT Stock Holding History

Squarepoint’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-118,620
Closed -$620K – 4922
2026
Q1 		$620K Buy
118,620
+33,887
+40% +$189K ﹤0.01% 3167
2025
Q4 		$502K Buy
84,733
+49,668
+142% +$357K ﹤0.01% 3219
2025
Q3 		$241K Buy
+35,065
New +$284K ﹤0.01% 3819
2025
Q1 		– Sell
-50,484
Closed -$227K – 5323
2024
Q4 		$227K Buy
50,484
+21,195
+72% +$107K ﹤0.01% 4373
2024
Q3 		$81.1K Sell
29,289
-65,451
-69% -$202K ﹤0.01% 3913
2024
Q2 		$324K Buy
+94,740
New +$435K ﹤0.01% 3387
2023
Q4 		– Sell
-35,000
Closed -$308K – 4450
2023
Q3 		$308K Buy
+35,000
New +$466K ﹤0.01% 3139

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Squarepoint's SGMT Position: Q2 2026 in Review

Squarepoint sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 118,620 shares — an estimated $620K sold.

Squarepoint first reported a position in SGMT in Q3 2023 and held it in 7 quarters. The position peaked at $620K in Q1 2026. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Squarepoint reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 118,620 Sagimet Biosciences shares in Q2 2026, an estimated $620K.
  • Squarepoint first reported a position in Sagimet Biosciences in Q3 2023 and held it in 7 quarters.
  • Squarepoint's Sagimet Biosciences position peaked at $620K in Q1 2026.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.